Screener / SEC EDGAR /CIK 0001125376 /10-K filed Feb 4, 2026, compared with Feb 5, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Skilled Nursing Care Facilities

Ensign Group, Inc ENSG

Compare with peers Embed
Planned sales, announced before they happen

6 trading plans running, 29 Form 144 notices for $8.3M

10-Q, 10-K and Form 144
Plans running now 6 Chad A. Keetch, Dr. Ann S. Blouin, Marivic Uychiat, Swati B. Abbott, Suzanne D. Snapper
Plans adopted 36 reported since Apr 26, 2023 Form 144 notices 29 $8.3M the sellers expected to sell

What ENSG's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Sep 2, 2025 to Aug 27, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.

InsiderWhatDateReported in
Chad A. Keetch
Chief Investment Officer and Executive Vice President
Adopted 10b5-1 plan Sep 1, 2026 10-Q Oct 27, 2026
What the company wrote
Chad A. Keetch, Chief Investment Officer and Executive Vice President, entered into a Rule 10b5-1 trading arrangement on September 1, 2026. Pursuant to the 10b5-1 plan, Mr. Keetch may make gifts of the Company's common stock having an aggregate value of up to $300 thousand between November 30, 2026 and December 31, 2026.
Dr. Ann S. Blouin
a member of our Board of Directors
Adopted 10b5-1 plan Aug 27, 2026 10-Q Oct 27, 2026
What the company wrote
Dr. Ann S. Blouin, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on August 27, 2026. Dr. Blouin's 10b5-1 plan provides for the sale of up to 450 shares of the Company's common stock between November 30, 2026 and August 27, 2027.
Barry M. Smith
a member of our Board of Directors
Ended 10b5-1 plan Jun 10, 2026 10-Q Jul 27, 2026
What the company wrote
On June 10, 2026, Barry M. Smith, a member of our Board of Directors, terminated his previously disclosed Rule 10b5-1 trading arrangement, adopted on July 29, 2025, that provided for recurring monthly sale of up to 700 shares, for an aggregate of up to 8,400 shares of the Company's common stock between January 2, 2026 and December 31, 2026.
Daren J. Shaw
a member of our Board of Directors
Ended 10b5-1 plan May 13, 2026 10-Q Jul 27, 2026
What the company wrote
On May 13, 2026, Daren J. Shaw, a member of our Board of Directors, terminated his previously disclosed Rule 10b5-1 trading arrangement, adopted on May 7, 2025, that provided for the potential sale of up to 4,000 shares of the Company's common stock between August 15, 2025 and May 29, 2026.
Marivic Uychiat
a member of our Board of Directors
Adopted 10b5-1 plan May 6, 2026 10-Q Jul 27, 2026
What the company wrote
Marivic Uychiat, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on May 6, 2026. Ms. Uychiat's 10b5-1 Plan provides for the potential exercise of vested stock options and the sale of up to 559 shares of the Company's common stock between August 5, 2026 and May 4, 2027.
Dr. Ann S. Blouin
a member of our Board of Directors
Adopted 10b5-1 plan Mar 12, 2026 10-Q Apr 30, 2026
What the company wrote
Dr. Ann S. Blouin, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on March 12, 2026. Dr. Blouin's 10b5-1 Plan provides for the potential sale of up to 375 shares of the Company's common stock between June 12, 2026 and February 26, 2027.
Swati B. Abbott
a member of our Board of Directors
Adopted 10b5-1 plan Mar 2, 2026 10-Q Apr 30, 2026
What the company wrote
Swati B. Abbott, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on March 2, 2026. Ms. Abbott's 10b5-1 Plan provides for the potential sale of up to 1,100 shares of the Company's common stock between June 1, 2026 and March 1, 2027.
Spencer Burton
President and Chief Operations Officer
Adopted 10b5-1 plan Feb 9, 2026 10-Q Apr 30, 2026
What the company wrote
Spencer Burton, President and Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on February 9, 2026. Mr. Burton's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 4,719 shares of the Company's common stock between May 11, 2026 and October 30, 2026. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 2,500 shares of the Company's common stock between May 11, 2026 and October 30, 2026.
Dr. Ann S. Blouin
a member of our Board of Directors
Adopted 10b5-1 plan Nov 7, 2025 10-K Feb 4, 2026
What the company wrote
Dr. Ann S. Blouin, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on November 7, 2025. Dr. Blouin's 10b5-1 Plan provides for the potential sale of up to 375 shares of the Company's common stock between February 9, 2026 and November 5, 2026.
Mark V. Parkinson
a member of our Board of Directors
Adopted 10b5-1 plan Nov 6, 2025 10-K Feb 4, 2026
What the company wrote
Mark V. Parkinson, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on November 6, 2025. Mr. Parkinson's 10b5-1 Plan provides for the potential sale of up to 400 shares of the Company's common stock between February 9, 2026 and October 15, 2026.
Suzanne D. Snapper
Chief Financial Officer, Executive Vice President, and Director
Adopted 10b5-1 plan Sep 12, 2025 10-Q Nov 3, 2025
What the company wrote
Suzanne D. Snapper, Chief Financial Officer, Executive Vice President, and Director, entered into a Rule 10b5-1 trading arrangement on September 12, 2025. Ms. Snapper's 10b5-1 plan provides for the potential exercise of vested stock options and the associated sale of up to 16,516 shares of the Company's common stock between January 2, 2026 and May 21, 2027.
Beverly B. Wittekind
Executive Vice President and General Counsel
Adopted 10b5-1 plan Sep 2, 2025 10-Q Nov 3, 2025
What the company wrote
Beverly B. Wittekind, Executive Vice President and General Counsel, entered into a Rule 10b5-1 trading arrangement on September 2, 2025. Ms. Wittekind's 10b5-1 plan provides for the potential sale of up to 5,900 shares of the Company's common stock and also the potential exercise of vested stock options and the associated sale of up to 5,000 shares of the Company's common stock between December 12, 2025 and July 31, 2026.
Christopher R. Christensen
Co-founder, Former Executive Chairman, and Former Chairman of the Board
Adopted 10b5-1 plan Aug 19, 2025 10-Q Nov 3, 2025
What the company wrote
Christopher R. Christensen, Co-founder, Former Executive Chairman, and Former Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on August 19, 2025, prior to his retirement from the Board. Mr. Christensen's 10b5-1 plan provides for the potential exercise of vested stock options and the sale of up to 26,800 shares of the Company's common stock between November 21, 2025 and November 28, 2025.
Spencer Burton
President and Chief Operations Officer
Adopted 10b5-1 plan Aug 14, 2025 10-Q Nov 3, 2025
What the company wrote
Spencer Burton, President and Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on August 14, 2025. Mr. Burton's 10b5-1 plan provides for the potential exercise of vested stock options and the associated sale of up to 11,798 shares of the Company's common stock between November 17, 2025 and August 31, 2026. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 4,229 shares of the Company's common stock starting on November 17, 2025 and ending on August 31, 2026.
Barry R. Port
Chief Executive Officer and Chairman of the Board
Adopted 10b5-1 plan Aug 12, 2025 10-Q Nov 3, 2025
What the company wrote
Barry R. Port, Chief Executive Officer and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on August 12, 2025. Mr. Port's 10b5-1 plan provides for the potential exercise of vested stock options and the associated sale of up to 28,315 shares of the Company's common stock between November 12, 2025 and August 31, 2026.
Dr. John O. Agwunobi
a member of our Board of Directors
Adopted 10b5-1 plan Jul 31, 2025 10-Q Nov 3, 2025
What the company wrote
Dr. John O. Agwunobi, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on July 31, 2025. Dr. Agwunobi's 10b5-1 plan provides for the potential sale of up to 1,421 shares of the Company's common stock between October 30, 2025 and July 20, 2026.
Barry M. Smith
a member of our Board of Directors
Adopted 10b5-1 plan Jul 29, 2025 10-Q Nov 3, 2025
What the company wrote
Barry M. Smith, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on July 29, 2025. Mr. Smith's 10b5-1 plan provides for the recurring monthly sale of up to 700 shares, for a total of up to 8,400 shares of the Company's common stock between January 2, 2026 and December 31, 2026.
Daren J. Shaw
a member of our Board of Directors
Adopted 10b5-1 plan May 7, 2025 10-Q Jul 24, 2025
What the company wrote
Daren J. Shaw, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on May 7, 2025. Mr. Shaw's 10b5-1 Plan provides for the potential sale of up to 4,000 shares of the Company's common stock between August 15, 2025 and May 29, 2026.
Dr. Ann S. Blouin
a member of our Board of Directors
Adopted 10b5-1 plan May 2, 2025 10-Q Jul 24, 2025
What the company wrote
Dr. Ann S. Blouin, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on May 02, 2025. Dr. Blouin's 10b5-1 Plan provides for the potential sale of up to 425 shares of the Company's common stock between July 31, 2025 and April 30, 2026.
Suzanne D. Snapper
Chief Financial Officer, Executive Vice President, and Director
Adopted 10b5-1 plan Nov 15, 2024 10-K Feb 5, 2025
What the company wrote
Suzanne D. Snapper, Chief Financial Officer, Executive Vice President, and Director, entered into a Rule 10b5-1 trading arrangement on November 15, 2024. Ms. Snapper's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,618 shares of the Company's common stock between February 18, 2025 and July 28, 2025.
Dr. Ann S. Blouin
a member of our Board of Directors
Adopted 10b5-1 plan Nov 12, 2024 10-K Feb 5, 2025
What the company wrote
Dr. Ann S. Blouin, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on November 12, 2024. Dr. Blouin's 10b5-1 Plan provides for the sale of up to 450 shares of the Company's common stock between February 11, 2025 and November 11, 2025.
Beverly B. Wittekind
Executive Vice President and General Counsel
Adopted 10b5-1 plan Sep 12, 2024 10-Q Oct 24, 2024
What the company wrote
Beverly B. Wittekind, Executive Vice President and General Counsel, entered into a Rule 10b5-1 trading arrangement on September 12, 2024. Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 8,258 shares of the Company's common stock between December 12, 2024 and July 31, 2025.
Christopher R. Christensen
Co-founder, Executive Chairman and Chairman of the Board
Adopted 10b5-1 plan Sep 10, 2024 10-Q Oct 24, 2024
What the company wrote
Christopher R. Christensen, Co-founder, Executive Chairman and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on September 10, 2024. Mr. Christensen's 10b5-1 Plan provides for the potential exercise of vested stock options and the sale of up to 39,086 shares of the Company's common stock between December 18, 2024 and June 18, 2025.
Spencer Burton
President & Chief Operations Officer
Adopted 10b5-1 plan Aug 8, 2024 10-Q Oct 24, 2024
What the company wrote
Spencer Burton, President & Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on August 8, 2024. Mr. Burton's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 5,899 shares of the Company's common stock between November 8, 2024 and August 8, 2025. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 4,229 shares of the Company's common stock starting on January 2, 2025.
Barry M. Smith
a member of our Board of Directors
Adopted 10b5-1 plan Jul 31, 2024 10-Q Oct 24, 2024
What the company wrote
Barry M. Smith, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on July 31, 2024. Mr. Smith's 10b5-1 Plan provides for the recurring monthly sale of up to 700 shares, for a total of up to 8,400 shares of the Company's common stock between January 2, 2025 and January 2, 2026.
Dr. Ann S. Blouin
a member of our Board of Directors
Adopted 10b5-1 plan Jul 31, 2024 10-Q Oct 24, 2024
What the company wrote
Dr. Ann S. Blouin, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on July 31, 2024. Dr. Blouin's 10b5-1 Plan provides for the sale of up to 375 shares of the Company's common stock between November 1, 2024 and July 29, 2025.
Swati B. Abbott
a member of our Board of Directors
Adopted 10b5-1 plan Jun 11, 2024 10-Q Jul 25, 2024
What the company wrote
Swati B. Abbott, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on June 11, 2024. Ms. Abbott's 10b5-1 Plan provides for the potential sale of up to 1,000 shares of the Company's common stock between September 13, 2024 and June 13, 2025.
Barry R. Port
Chief Executive Officer and Director
Adopted 10b5-1 plan May 6, 2024 10-Q Jul 25, 2024
What the company wrote
Barry R. Port, Chief Executive Officer and Director, entered into a Rule 10b5-1 trading arrangement on May 6, 2024. Mr. Port's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 16,517 shares of the Company's common stock between August 5, 2024 and August 31, 2026.
Daren J. Shaw
a member of our Board of Directors
Adopted 10b5-1 plan May 6, 2024 10-Q Jul 25, 2024
What the company wrote
Daren J. Shaw, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on May 6, 2024. Mr. Shaw's 10b5-1 Plan provides for the potential sale of up to 8,000 shares of the Company's common stock between August 15, 2024 and May 30, 2025.
Chad A. Keetch
Chief Investment Officer, Executive Vice President & Secretary
Adopted 10b5-1 plan Mar 6, 2024 10-Q May 1, 2024
What the company wrote
Chad A. Keetch, Chief Investment Officer, Executive Vice President & Secretary, entered into a Rule 10b5-1 trading arrangement on March 6, 2024. Mr. Keetch's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 27,134 shares of the Company's common stock between June 5, 2024 and October 31, 2024.
Spencer W. Burton
President & Chief Operations Officer
Adopted 10b5-1 plan Feb 9, 2024 10-Q May 1, 2024
What the company wrote
Spencer W. Burton, President & Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on February 9, 2024. Mr. Burton's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,618 shares of the Company's common stock between May 10, 2024 and July 30, 2025. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 4,725 shares of the Company's common stock on May 10, 2024.
Ann S. Blouin
a member of our Board of Directors
Adopted 10b5-1 plan Feb 6, 2024 10-Q May 1, 2024
What the company wrote
Ann S. Blouin, a member of our Board of Directors, entered into a Rule 10b5-1 trading arrangement on February 6, 2024. Dr. Blouin's 10b5-1 Plan provides for the potential sale of up to 350 shares of the Company's common stock between May 7, 2024 and February 5, 2025.
Beverly B. Wittekind
Vice President & General Counsel
Adopted 10b5-1 plan Dec 8, 2023 10-K Feb 1, 2024
What the company wrote
Beverly B. Wittekind, Vice President & General Counsel, entered into a Rule 10b5-1 trading arrangement on December 8, 2023 (the "Rule 10b5-1 Plan"). Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,000 shares of the Company's common stock between March 14, 2024 and October 31, 2024.
Christopher R. Christensen
Co-founder, Executive Chairman and Chairman of the Board
Adopted 10b5-1 plan Nov 2, 2023 10-K Feb 1, 2024
What the company wrote
Christopher R. Christensen, Co-founder, Executive Chairman and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on November 2, 2023 (the "Rule 10b5-1 Plan"). Mr. Christensen's 10b5-1 Plan provides for the potential sale of up to 110,700 shares of the Company's common stock between February 6, 2024 and December 31, 2024.
Spencer W. Burton
President & Chief Operations Officer
Adopted 10b5-1 plan Sep 12, 2023 10-Q Oct 25, 2023
What the company wrote
Spencer W. Burton, President & Chief Operations Officer, entered into a Rule 10b5-1 trading arrangement on September 12, 2023 (the "Rule 10b5-1 Plan"). Mr. Burton's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 8,280 shares of the Company's common stock between December 14, 2023 and August 30, 2024. Pursuant to the 10b5-1 Plan, Mr. Burton may also make a gift of up to 2,380 shares of the Company's common stock starting on December 14, 2023.
Daren J. Shaw
member of our Board of Directors
Adopted 10b5-1 plan May 23, 2023 10-Q Jul 27, 2023
Chad A. Keetch
Chief Investment Officer, Executive Vice President & Secretary
Adopted 10b5-1 plan May 5, 2023 10-Q Jul 27, 2023
Ann S. Blouin
member of our Board of Directors
Adopted 10b5-1 plan May 1, 2023 10-Q Jul 27, 2023
Show the other 30 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since Apr 26, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Oct 16, 2026 Parkinson Mark Vincent
Director
100 $18K
Jul 27, 2026 Blouin Ann Scott
Director
375 $69K
Jul 20, 2026 Agwunobi John O
Director
392 $67K
Jul 16, 2026 Parkinson Mark Vincent
Director
100 $17K
Jun 2, 2026 SMITH BARRY M
Director
700 $115K
May 4, 2026 SMITH BARRY M
Director
700 $128K
Apr 20, 2026 Agwunobi John O
Director
392 $78K
Apr 16, 2026 Parkinson Mark Vincent
Director
100 $20K
Apr 2, 2026 SMITH BARRY M
Director
700 $138K
Mar 2, 2026 SMITH BARRY M
Director
700 $149K
Feb 20, 2026 Uychiat Pison Marivic
Officer, Director
67 $14K
Feb 19, 2026 Uychiat Pison Marivic
Officer, Director
83 $18K
Feb 19, 2026 Wittekind Beverly B.
Officer
500 $105K
Feb 17, 2026 Shaw Daren
Director
1,000 $213K
Feb 9, 2026 Blouin Ann Scott
Director
375 $74K
Feb 9, 2026 Parkinson Mark Vincent
Director
100 $20K
Feb 6, 2026 Snapper Suzanne D.
Officer, Director
4,573 $897K
Feb 5, 2026 Snapper Suzanne D.
Officer, Director
8,258 $1.6M
Feb 2, 2026 SMITH BARRY M
Director
700 $120K
Jan 21, 2026 Agwunobi John O
Director
146 $26K
Jan 20, 2026 Agwunobi John O
Director
246 $44K
Jan 2, 2026 SMITH BARRY M
Director
700 $122K
Dec 19, 2025 Wittekind Beverly B.
Officer
2,000 $360K
Dec 12, 2025 Wittekind Beverly B.
Officer
8,400 $1.5M
Dec 1, 2025 SMITH BARRY M
Director
700 $129K
Nov 20, 2025 Burton Spencer
Officer
3,690 $664K
Nov 18, 2025 Burton Spencer
Officer
2,209 $398K
Nov 18, 2025 Shaw Daren
Director
1,000 $179K
Nov 17, 2025 Burton Spencer
Officer
5,899 $1.0M
Show the other 21 notices

From the Form 144 XML filed with the SEC, since Nov 17, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENSG/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.